Back to results
US 2020/0283738 A1Published application
Tymovirus virus and virus-like particles as nanocarriers for imaging and therapeutic agents
AssigneeCase Western Reserve University
InventorsNicole F. Steinmetz, Hema Masarapu, He Hu
Life of this patent
Estimating the term…
Abstract
A method of targeting cancer tissue in a subject includes administering to the subject a plurality of functionalized Tymovirus virus or virus-like particles loaded with or conjugated to an imaging agent, a therapeutic agent or a targeting agent.
Claims17
1:
- A method of treating and/or detecting cancer tissue in a subject comprising administering to the subject a plurality of functionalized Tymovirus virus or Tymovirus virus-like particles (VLPs) loaded with or conjugated to one or more of a therapeutic agent, an imaging agent, or a targeting agent.
2:
- The method of claim 1, wherein the Tymovirus virus belongs to the physalis mottle virus (PhMV) species.
3:
- The method of claim 1, wherein the Tymovirus virus or VLPs have been PEGylated.
4:
- The method of claim 1, wherein the Tymovirus virus or VLPs comprise an imaging agent.
5:
- The method of claim 4, wherein the imaging agent is a fluorescent molecule for fluorescent imaging or a chelated metal for MRI imaging.
6:
- The method of claim 5, wherein the Tymovirus virus or VLPs are administered at an effective amount, and further comprising the step of imaging cancer tissue in the subject using an imaging device subsequent to administering the Tymovirus virus or VLPs.
7:
- The method of claim 1, wherein the Tymovirus virus or VLPs comprise a therapeutic agent.
8:
- The method of claim 7, wherein the therapeutic agent is an antitumor agent.
9:
- The method of claim 8, wherein the antitumor agent is selected from doxorubicin and mitoxantrone.
10:
- The method of claim 1, wherein the cancer tissue is prostate cancer, breast cancer, or ovarian cancer tissue.
11:
- The method of claim 1, wherein the therapeutic agent is a photodynamic therapeutic (PDT) photosensitizer agent.
12:
- The method of claim 11, the PDT agent selected from a porphyrin or a mettalloporphyrin compound.
13:
- The method of claim 12, wherein the porphyrin is a cationic zinc ethynylphenyl porphyrin.
14:
- The method of claim 1, wherein the one or more of a therapeutic agent, an imaging agent, or a targeting agent is directly conjugated to the Tymovirus virus or VLPs.
15:
- The method of claim 1, wherein the one or more of a therapeutic agent, an imaging agent, or a targeting agent is conjugated to the Tymovirus virus or VLPs via a linker.
16:
- The method of claim 1, including multiple targeting agents, wherein the spacing and location of targeting agents on each Tymovirus virus or VLP is controlled to facilitate delivery, targeting, and/or therapeutic efficacy of the Tymovirus virus or VLP.
17-56. (canceled)